aTyr Pharma Management

Management criteria checks 2/4

aTyr Pharma's CEO is Sanjay Shukla, appointed in Nov 2017, has a tenure of 6.33 years. total yearly compensation is $2.41M, comprised of 23.3% salary and 76.7% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $233.10K. The average tenure of the management team and the board of directors is 5.5 years and 14.4 years respectively.

Key information

Sanjay Shukla

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage23.3%
CEO tenure6.3yrs
CEO ownership0.2%
Management average tenure5.5yrs
Board average tenure14.4yrs

Recent management updates

Recent updates

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

CEO Compensation Analysis

How has Sanjay Shukla's remuneration changed compared to aTyr Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$1mUS$450k

-US$35m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$45m

Dec 31 2017US$2mUS$403k

-US$48m

Compensation vs Market: Sanjay's total compensation ($USD2.41M) is above average for companies of similar size in the US market ($USD658.28K).

Compensation vs Earnings: Sanjay's compensation has increased whilst the company is unprofitable.


CEO

Sanjay Shukla (51 yo)

6.3yrs

Tenure

US$2,411,435

Compensation

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...


Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Shukla
President6.3yrsUS$2.41m0.17%
$ 233.1k
Jill Broadfoot
Chief Financial Officer5.7yrsUS$913.49k0.023%
$ 30.9k
Nancy E. Krueger
General Counsel & Corporate Secretary9.4yrsUS$857.53k0.022%
$ 29.5k
Xiang-Lei Yang
Founderno datano datano data
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno datano datano data
Peter Villiger
Vice President of Corporate Development4.2yrsno datano data
Danielle Campbell
VP of Human Resource2.3yrsno datano data
Leslie Nangle
Vice President of Researchno datano datano data
Ying Buechler
Executive Director of Biologics Development & Manufacturingno datano datano data
David King
Scientific Consultant5.3yrsUS$717.31kno data

5.5yrs

Average Tenure

58yo

Average Age

Experienced Management: LIFE's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sanjay Shukla
President6.3yrsUS$2.41m0.17%
$ 233.1k
John Clarke
Independent Directorno dataUS$128.10k0.029%
$ 39.6k
Paul Schimmel
Independent Director18.5yrsUS$65.33k1.48%
$ 2.0m
Floyd Bloom
Member of Scientific Advisory Board14.4yrsno datano data
Bruce Beutler
Member of Scientific Advisory Board14.6yrsno datano data
Benjamin Cravatt
Member of Scientific Advisory Boardno datano datano data
Timothy Coughlin
Independent Chairman of the Board6.9yrsUS$96.24k0.0089%
$ 12.0k
Osamu Nureki
Member of Scientific Advisory Board14.5yrsno datano data
Susan Ackerman
Member of Scientific Advisory Boardno datano datano data
Wing Wong
Member of Scientific Advisory Boardno datano datano data
Nancy Ip
Member of Scientific Advisory Boardno datano datano data
Jane Gross
Independent Director4.7yrsUS$71.24k0.0089%
$ 12.0k

14.4yrs

Average Tenure

66yo

Average Age

Experienced Board: LIFE's board of directors are seasoned and experienced ( 14.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.